HOWL

Werewolf Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001785530
$0.3810 -3.30% $18.5M
Insider Selling Cluster (2 insiders)4 Institutional Exits
Vol
Market Cap$18.5M
Cap SizeNano Cap
Inst. Holders19 funds
Inst. Value$7.7M
Inst. Activity0 buys / 4 sells
Insider Activity0B / 35S
Insider Net $-$1.7M
SEC Reports12
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001785530·Prev Close $0.3940

Recent Activity

Jun 12, 2026 SEC
Two insiders at Werewolf Therapeutics — a director and a 10% owner — sold a total of ~$156K in open-market sales over tw
CLUSTER — Impact 5/10
Jun 11, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. sold 245,066 shares
10%+ Owner @ $0.3800 ($93.1K)
Jun 10, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. sold 42,872 shares
10%+ Owner @ $0.3700 ($15.9K)
Jun 9, 2026 Insider
EVNIN LUKE sold 76,928 shares
Director @ $0.3700 ($28.5K)
Jun 8, 2026 short_volume
Short Volume: HOWL — 59.2% short (0.3M / 0.5M)
Short: 296,905 | Exempt: 14,928 | TRF Vol: 501,352 | Short Ratio: 59.2% | Off-exchange volume (dark
May 28, 2026 SEC
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Onc
144 — Impact 6/10
May 20, 2026 SEC
Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-day window, represen
CLUSTER — Impact 4/10
Inst.
BANK OF AMERICA CORP — TRIM
264,583 shares ($220.1K)

Price Targets

Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$4.00 (Dec 2025)
Current $0.3810 Low $4.00 Median $4.00 High $4.00 1 analysts
$4.00 $4.00

Analyst Ratings

Historical distribution80% buy · 10 analysts · last covering-analyst action Dec 2025
4Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
Dec 19, 2025 HC Wainwright & Co. MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.28 ▲ +6.7% $-0.28 — $-0.28 30% YoY 1
Next Q $-0.22 ▲ +18.5% $-0.22 — $-0.22 39% YoY 1
Current FY $-0.89 ▲ +17.6% $-0.89 — $-0.89 33% YoY 1
Next FY $-0.99 ▲ +22.0% $-0.99 — $-0.99 -11% YoY 1

Latest Reports

BEARISH CLUSTER 5/10
Two insiders at Werewolf Therapeutics — a director and a 10% owner — sold a total of ~$156K in open-market sales over tw
Jun 12, 2026
BEARISH 144 6/10
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Onc
May 28, 2026

Top Institutional Holders

FundValueMove
RA CAPITAL MANAGEMENT, L.P.$5.6M—
VANGUARD CAPITAL MANAGEMENT LLC$1.0M—
RENAISSANCE TECHNOLOGIES LLC$429.8KADD
BANK OF AMERICA CORP$220.1KTRIM
VANGUARD FIDUCIARY TRUST CO$131.4K—

Recent Insider Trades

DateInsiderTypeValue
Jun 11, 2026RA CAPITALSELL$93.1K
Jun 10, 2026RA CAPITALSELL$15.9K
Jun 9, 2026EVNIN LUKESELL$28.5K
Jun 9, 2026RA CAPITALSELL$127.7K
Jun 8, 2026EVNIN LUKESELL$24.2K
19 institutional holders with $7.7M total value (9,294,298 shares) as of 2026-Q1. Top holders: RA, VANGUARD, RENAISSANCE. Net selling activity: 4 institutions trimmed/exited vs 0 added.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1RA CAPITAL MANAGEMENT, L.P.6,681,307$5.6M72.0%—
2VANGUARD CAPITAL MANAGEMENT LLC1,217,976$1.0M13.1%—
3RENAISSANCE TECHNOLOGIES LLC516,218$429.8K5.6%ADD +48.6%
4BANK OF AMERICA CORP /DE/264,583$220.1K2.8%TRIM -64.1%
5VANGUARD FIDUCIARY TRUST CO157,726$131.4K1.7%—
6STATE STREET CORP119,168$99.2K1.3%TRIM -73.2%
7BlackRock, Inc.101,608$84.6K1.1%TRIM -72.0%
8Alyeska Investment Group, L.P.86,554$72.1K0.9%TRIM -63.3%
9GOLDMAN SACHS GROUP INC38,266$31.9K0.4%—
10MORGAN STANLEY33,799$28.1K0.4%TRIM -26.5%
11RAYMOND JAMES FINANCIAL INC19,778$16.5K0.2%—
12BARCLAYS PLC13,235$11.0K0.1%TRIM -70.8%
13CITADEL ADVISORS LLC10,382$8.6K0.1%NEAR_EXIT -82.0%
14Vanguard Global Advisers, LLC10,343$8.6K0.1%—
15CITIGROUP INC3,384$2.8K0.0%DOUBLED +238.8%
16GROUP ONE TRADING LLC1,871$1.6K0.0%TRIM -30.0%
17NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO200$167.000.0%—
18FMR LLC39$32.000.0%NEAR_EXIT -98.9%
19HRT FINANCIAL LP17,861$14.000.0%—

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BANK OF AMERICA CORP /DE/TRIM737,550264,583-64.1%$220.1K2026-Q1
Alyeska Investment Group, L.P.TRIM235,70586,554-63.3%$72.1K2026-Q1
MORGAN STANLEYTRIM46,00233,799-26.5%$28.1K2026-Q1
FMR LLCNEAR_EXIT3,63139-98.9%$32.002026-Q1
BANK OF AMERICA CORP /DE/TRIM1,830,292737,550-59.7%$466.9K2025-Q4
RENAISSANCE TECHNOLOGIES LLCADD456,000677,766+48.6%$429.4K2025-Q4
MORGAN STANLEYDOUBLED19,25246,002+138.9%$29.1K2025-Q4
FMR LLCTRIM11,2843,631-67.8%$2.3K2025-Q4
GROUP ONE TRADING LLCTRIM2,6711,871-30.0%$1.2K2025-Q4
NISA INVESTMENT ADVISORS, LLCTRIM1,375345-74.9%$219.002025-Q4
RENAISSANCE TECHNOLOGIES LLCADD316,300456,000+44.2%$898.3K2025-Q3
BlackRock, Inc.TRIM361,983101,323-72.0%$199.6K2025-Q3
TWO SIGMA INVESTMENTS, LPTRIM45,42220,139-55.7%$39.7K2025-Q3
MORGAN STANLEYTRIM27,20019,252-29.2%$37.9K2025-Q3
UBS Group AGDOUBLED3,43812,776+271.6%$25.2K2025-Q3
CWM, LLCNEAR_EXIT8,4481,569-81.4%$3.002025-Q3
RENAISSANCE TECHNOLOGIES LLCDOUBLED63,900316,300+395.0%$344.8K2025-Q2
STATE STREET CORPTRIM444,272119,168-73.2%$129.9K2025-Q2
ROYAL BANK OF CANADADOUBLED2,77910,543+279.4%$11.0K2025-Q2
FEDERATED HERMES, INC.TRIM6,1304,387-28.4%$4.8K2025-Q2
UBS Group AGNEAR_EXIT17,6883,438-80.6%$3.7K2025-Q2
WELLS FARGO & COMPANY/MNNEAR_EXIT17,856459-97.4%$500.002025-Q2
BARCLAYS PLCTRIM45,36113,236-70.8%$14.002025-Q2
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD71,86095,712+33.2%$93.1K2025-Q1
DIMENSIONAL FUND ADVISORS LPTRIM194,74684,607-56.6%$82.4K2025-Q1
2 unique insiders with 35 transactions. Net insider value: -$1.7M ($0.00 bought, $1.7M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 11, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL245,066$0.3800$93.1K
Jun 10, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL42,872$0.3700$15.9K
Jun 9, 2026EVNIN LUKEDirectorSELL76,928$0.3700$28.5K
Jun 9, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL345,235$0.3700$127.7K
Jun 8, 2026EVNIN LUKEDirectorSELL60,547$0.4000$24.2K
Jun 5, 2026EVNIN LUKEDirectorSELL24,946$0.4000$10.0K
Jun 4, 2026EVNIN LUKEDirectorSELL20,072$0.4400$8.8K
Jun 3, 2026EVNIN LUKEDirectorSELL29,749$0.4200$12.5K
Jun 2, 2026EVNIN LUKEDirectorSELL29,595$0.4500$13.3K
Jun 1, 2026EVNIN LUKEDirectorSELL80,459$0.4700$37.8K
May 29, 2026EVNIN LUKEDirectorSELL32,556$0.4500$14.7K
May 28, 2026EVNIN LUKEDirectorSELL27,698$0.4600$12.7K
May 27, 2026EVNIN LUKEDirectorSELL80,852$0.4800$38.8K
May 26, 2026EVNIN LUKEDirectorSELL67,950$0.4700$31.9K
May 22, 2026EVNIN LUKEDirectorSELL87,425$0.4500$39.3K
May 21, 2026EVNIN LUKEDirectorSELL36,387$0.4200$15.3K
May 20, 2026EVNIN LUKEDirectorSELL85,895$0.4300$36.9K
May 19, 2026EVNIN LUKEDirectorSELL62,970$0.4500$28.3K
May 18, 2026EVNIN LUKEDirectorSELL22,184$0.5000$11.1K
May 13, 2026EVNIN LUKEDirectorSELL44,679$0.5400$24.1K
May 12, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL94,432$0.6400$60.4K
May 12, 2026EVNIN LUKEDirectorSELL67,885$0.6400$43.4K
May 11, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL81,678$0.6700$54.7K
May 11, 2026EVNIN LUKEDirectorSELL33,948$0.6700$22.7K
May 8, 2026RA CAPITAL MANAGEMENT, L.P.10%+ OwnerSELL351,514$0.7100$249.6K
May 8, 2026EVNIN LUKEDirectorSELL305,741$0.7000$214.0K
May 7, 2026EVNIN LUKEDirectorSELL79,086$0.6300$49.8K
May 6, 2026EVNIN LUKEDirectorSELL14,635$0.6600$9.7K
May 5, 2026EVNIN LUKEDirectorSELL6,860$0.6900$4.7K
May 4, 2026EVNIN LUKEDirectorSELL47,963$0.7200$34.5K
May 1, 2026EVNIN LUKEDirectorSELL58,394$0.7300$42.6K
Apr 30, 2026EVNIN LUKEDirectorSELL168,262$0.7200$121.1K
Apr 29, 2026EVNIN LUKEDirectorSELL56,559$0.6900$39.0K
Apr 28, 2026EVNIN LUKEDirectorSELL95,412$0.7300$69.7K
Apr 27, 2026EVNIN LUKEDirectorSELL53,940$0.8500$45.8K
12 SEC filing reports analyzed. Sentiment: 0 bullish, 7 bearish, 0 mixed, 5 neutral. Avg impact: 4.4/10.
BEARISH CLUSTER 5/10
Two insiders at Werewolf Therapeutics — a director and a 10% owner — sold a total of ~$156K in open-
Jun 12, 2026
BEARISH 144 6/10
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset
May 28, 2026
NEUTRAL CLUSTER 4/10
Director Luke Evnin and 10% owner RA Capital Management sold a combined $72K in HOWL stock over a 7-
May 20, 2026
BEARISH 144 6/10
Three MPM-affiliated funds (MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., and MPM Onco
May 18, 2026
BEARISH CLUSTER 6/10
Two insiders at Werewolf Therapeutics sold a total of $299K in open-market sales over a 7-day window
May 12, 2026
BEARISH 144 6/10
Two affiliated MPM entities (MPM Asset Management LLC and MPM Oncology Innovations Fund LP) filed Fo
May 11, 2026
NEUTRAL 144 2/10
MPM Asset Management Investors BV2014 LLC, a venture capital affiliate, filed a Form 144 indicating
May 1, 2026
NEUTRAL 144 4/10
Two major institutional holders—MPM BioVentures 2014 (B), L.P. and UBS Oncology Impact Fund L.P.—fil
May 1, 2026
BEARISH 144 5/10
Three affiliated MPM entities – MPM Asset Management LLC, MPM Oncology Innovations Fund LP, and MPM
May 1, 2026
NEUTRAL 144 2/10
MPM Asset Management LLC, a major shareholder of Werewolf Therapeutics, filed a Form 144 indicating
Apr 29, 2026
NEUTRAL 144 2/10
MPM Asset Management Investors BV2014 LLC, a venture capital fund, filed a Form 144 to sell 4,479 sh
Apr 29, 2026
BEARISH 144 5/10
Four MPM-affiliated funds filed Form 144 notices to sell an aggregate of 274,913 shares of Werewolf
Apr 27, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Dec 2025): 80% buy across 10 analysts — 4 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.

Analyst Price Targets

Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$4.00 mean target (Dec 2025)
$4.00 Low $4.00 High
MetricValue
Current Price$0.3810
Target Low$4.00
Target Mean$4.00
Target Median$4.00
Target High$4.00
# Analysts1
Recommendation— (no recent coverage)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.28 $-0.28 $-0.28 30.0% +6.7% 1↑ 0↓ $0.0B 0.0% 1
Next Q
2026-09-30
 $-0.22 $-0.22 $-0.22 38.9% +18.5% 1↑ 0↓ $0.0B 0.0% 1
Current FY
2026-12-31
 $-0.89 $-0.89 $-0.89 32.6% +17.6% 0↑ 1↓ $0.0B 0.0% 1
Next FY
2027-12-31
 $-0.99 $-0.99 $-0.99 -11.2% +22.0% 1↑ 0↓ $0.0B 0.0% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.280
7d ago$-0.300+0.020
30d ago$-0.300+0.020
60d ago$-0.333+0.053
90d ago$-0.333+0.053
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Dec 19, 2025 HC Wainwright & Co. MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20264420080%
May 1, 20264420080%
Apr 1, 20265420082%
Mar 1, 20265430075%
Feb 1, 20265430075%
Jan 1, 20265430075%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 8, 2026
short_volume
Short Volume: HOWL — 59.2% short (0.3M / 0.5M)
Short: 296,905 | Exempt: 14,928 | TRF Vol: 501,352 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
HOWL Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
earnings_calendar
HOWL Q1 2026 Earnings Scheduled — 2026-05-01
Mar 27, 2026
earnings
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value <pre>Company continues to evaluate strategic options to maximize shareho
Mar 19, 2026
earnings_calendar
HOWL Q4 2025 Earnings After Market Close — 2026-03-19
Mar 2, 2026
earnings_calendar
HOWL Q4 2025 Earnings After Market Close — 2026-03-02